title: Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma.
abstract: Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) is one of the most frequently applied standard treatments for this disease. The role for TACE is fairly well defined within the most widely used treatment algorithm for HCC, die Barcelona Clinic Liver Cancer (BCLC) staging system and treatment algorithm. But no general treatment algorithm will go into the technical details of any procedure and several patients will not fit ideally into the patient groups predefined in BCLC or any other treatment algorithm. Furthermore, indications and contraindications sometimes are viewed differently by the various medical specialties involved in taking care of such patients. We present here the joint expert position statement of the Austrian Societies of Gastroenterology and Hepatology (ÖGGH), Interventional Radiology (ÖGIR), Hematology and Oncology (ÖGHO), and Surgical Oncology (ASSO) on the technical aspects, indications, and contraindication for the use of TACE in the management of HCC.
authors.affiliation: Abteilung Gastroenterologie & Hepatologie, KIM III, AKH & MedUniWien, Vienna, Austria. markus.peck@meduniwien.ac.at
authors.forename: Markus
authors.initials: M
authors.lastname: Peck-Radosavljevic
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Sieghart
authors.forename: Claus
authors.initials: C
authors.lastname: Kölblinger
authors.forename: Markus
authors.initials: M
authors.lastname: Reiter
authors.forename: Martin
authors.initials: M
authors.lastname: Schindl
authors.forename: Gregor
authors.initials: G
authors.lastname: Ulbrich
authors.forename: Rudolf
authors.initials: R
authors.lastname: Steininger
authors.forename: Christian
authors.initials: C
authors.lastname: Müller
authors.forename: Rudolf
authors.initials: R
authors.lastname: Stauber
authors.forename: Maximilian
authors.initials: M
authors.lastname: Schöniger-Hekele
authors.forename: Manfred
authors.initials: M
authors.lastname: Gschwendtner
authors.forename: Christina
authors.initials: C
authors.lastname: Plank
authors.forename: Martin
authors.initials: M
authors.lastname: Funovics
authors.forename: Ivo
authors.initials: I
authors.lastname: Graziadei
authors.forename: Johannes
authors.initials: J
authors.lastname: Lammer
authors.forename: Thomas
authors.initials: T
authors.lastname: Gruenberger
authors.forename: Günther
authors.initials: G
authors.lastname: Gastl
authors.forename: Franz
authors.initials: F
authors.lastname: Karnel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001317:Austria; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000592:standards*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008495:Medical Oncology / Q000592:standards*; D017410:Practice Guidelines as Topic
chemical_list: D000970:Antineoplastic Agents